Trial Profile
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Pafolacianine (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors On Target Laboratories
- 15 Oct 2019 According to an On Target Laboratories media release, results of this study were published in Gynecologic Oncology Journal.
- 15 Oct 2019 Results presented in an On Target Laboratories media release.
- 27 Jul 2019 Results assessing safety and efficacy of OTL-38 in patients with ovarian cancer patients, published in the Gynecologic Oncology.